Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10354272 | 0.75 | CNR1 (0.46) | CNR1SOAT1MEN1FAAHTP53 | |
| SCHEMBL6941914 | 0.74 | HDAC2 (0.41) | CNR1SOAT1MEN1FAAHTP53 | |
| SCHEMBL7094787 | 0.72 | — | — | |
| SCHEMBL4825533 | 0.71 | HDAC2 (0.50) | SOAT1MEN1FAAHTP53CYP1A2 | |
| SCHEMBL15774854 | 0.69 | CNR1 (0.42) | CNR1SOAT1MEN1FAAHTP53 | |
| SCHEMBL6644124 | 0.69 | — | — | |
| SCHEMBL435772 | 0.68 | — | — | |
| SCHEMBL6068913 | 0.67 | — | — | |
| SCHEMBL6467649 | 0.66 | FAAH (0.58) | CNR1SOAT1MEN1FAAHTP53 | |
| SCHEMBL6069030 | 0.66 | CNR1 (0.53) | CNR1SOAT1MEN1FAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323596-B2 | Antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH( .dbd. O) or of formula C( .dbd. O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of | DE NOVO PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20040102491-A1 | Antimicrobial agents | DE NOVO PHARMACEUTICALS LTD. (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1343753-A2 | ANTIMICROBIAL AGENTS | De Novo Pharmaceuticals Ltd. (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050081-A2 | ANTIMICROBIAL AGENTS | DE NOVO PHARMACEUTICALS LTD (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102491-A1 | Antimicrobial agents | CBR1, CYC1, MRM1 | CNR1 422/4885SOAT1 585/4885MEN1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.